



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498/PTO		<b>Complete if Known</b>			
		Application Number	10/090,983		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	March 4, 2002		
		First Named Inventor	MANNING JR., WILLIAM C.		
		Group/Art Unit	1632		
		Examiner Name	BERTOGLIO, VALARIE E.		
Sheet	2	of	2	Attorney Docket Number	BERK-010DIV

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		CAYOQUETTE M et al. "Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration Mouse", Human Gene Therapy Vol. 8, No. 4, March 1, 1997 pages 423-430	
		AKIMOTO et al. "Adenovirally Expressed Basic Fibroblast Growth Factor Rescues Photoreceptor Cells in RCS Rats", IOVS, Vol. 40, February 1999, pages 273-279	
		PETERSON et al. "Enhanced Survival of Photoreceptors in p23h Mutant Rhodopsin Transgenic Rats by Adeno-Associated Virus (AAV)-Mediated Delivery of Neurotrophic Genes", Vol. 39, March 15, 1998, page S1117	
		LUTHERT et al. "Photoreceptor Rescue" Eye, Vol.12, June 1998, pages 591-596	
		SMITH L.E.H. et al. "Inhibition of Retinal Neovascularization With an IGF-1 Receptor Antagonist"	
		SHAFIEE A. et al. "Thrombospondin Peptides Inhibit Angiogenesis in Retina Explant Assay and Rat Model of Retinopathy of Prematurity", Vol. 38, 1997 page 6964	
		FOTSIS T. et al. "The Endogenous Oestrogen Metabolite 2-Methoxyestradiol Inhibits Angiogenesis and Suppresses Tumor Growth", Nature, Vol. 368, 1994, pages 237-239	
		OIKAWA et al. "Three Novel Synthetic Retinoids, RE 80, AM580 and AM80, all Exhibit Anti-Angiogenic Activity In Vivo", European Journal of Pharmacology, Vol. 249, 1993, pages 113-116	

Examiner Signature		Date Considered	02.01.04
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-01)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
		Application Number	10/090,983
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	March 4, 2002
		First Named Inventor	MANNING JR., WILLIAM C.
		Art Unit	1632
		Examiner Name	BERTOGLIO, VALARIE E.
		Attorney Docket Number	BERK-010DIV
Sheet	1	of	2

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
VB		5,641,749		06-24-1997	Qiao Yan et al,	
VB		5,792,845		08-11-1998	Judith Folkman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 00/15822	03-23-2000	Jacques J Janssen		
		WO 00/01815	01-13-2000	Nikolaj Blom		
		WO 95/26409	10-05-1995	Marc Abitbol		
		WO 99/45052	09-16-1999	Genentech Inc.		
		WO 99/16889	04-08-1999	Mark Bolanowski		
		WO 98/51323	11-04-1998	Ingrid Stuman		
		WO 00/54813	09-21-2000	Chiron Corporation		
		WO 00/71582	11-30-2000	Human Genome Sciences		
		WO 99/36511	07-22-1999	Chiron Corporation		
		WO 99/86959	12-29-1999	Selective Genetics, Inc.		
		EP 407,122	01-09-1991	Repligen Corp.		
		WO 98/13071	04-02-1998	Richard Kendall		
		JP 11100327	04-13-1999	Toray Ind. Inc.		

Examiner Signature	<i>Valerio</i>	Date Considered	02.01.04
--------------------	----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
			Application Number	10/090,983
			Filing Date	March 4, 2002
			First Named Inventor	Manning
			Group Art Unit	1632
			Examiner Name	V. Bertoglio
Sheet 1 of 1	Attorney Docket Number	BERK-010DIV		

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
VB		TOLENTINO, et al., Vascular Endothelial Growth Factor is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman Primate, Arch Ophthalmol, Vol 114, pgs 964-970, August 1996	

Examiner Signature		Date Considered	02-01-04
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.